VANDA PHARMACEUTICALS INC (VNDA) Forecast, Price Target & Analyst Ratings
NASDAQ:VNDA • US9216591084
7.72 USD
-0.12 (-1.53%)
Last: Mar 4, 2026, 09:55 AM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for VANDA PHARMACEUTICALS INC (VNDA).
Forecast Snapshot
Consensus Price Target
$14.41
+ 86.63% Upside
Next Earnings Forecast
Release DateMay 5, 2026
PeriodQ1 / 2026
EPS Estimate-$0.73
Revenue Estimate54.545M
ChartMill Buy Consensus
80.00%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$14.41
Upside
+ 86.63%
From current price of $7.72 to mean target of $14.41, Based on 10 analyst forecasts
Low
$7.58
Median
$12.75
High
$25.20
Price Target Revisions
1 Month
3.67%
3 Months
20.21%
Price Target Summary
10 analysts have analysed VNDA and the average price target is 14.41 USD. This implies a price increase of 86.63% is expected in the next year compared to the current price of 7.72.
The average price target has been revised upward by 20.21% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
80.00%
VNDA was analyzed by 10 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about VNDA.
In the previous month the buy percentage consensus was at a similar level.
VNDA was analyzed by 10 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-23 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-01-05 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-12-31 | B. Riley Securities | Maintains | Buy -> Buy |
| 2025-12-31 | Jefferies | Maintains | Hold -> Hold |
| 2025-11-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-11-05 | B. Riley Securities | Initiate | Buy |
| 2025-10-30 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2025-08-21 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-05-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-04-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-18 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-02-04 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-28 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-21 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-23 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-31 | HC Wainwright & Co. | Initiate | Buy |
| 2024-08-01 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2024-07-11 | Cantor Fitzgerald | Initiate | Overweight |
| 2022-02-25 | Jefferies | Downgrade | Buy -> Hold |
| 2021-05-12 | B of A Securities | Initiate | Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateMay 5, 2026
PeriodQ1 / 2026
EPS Estimate-$0.73
Revenue Estimate54.545M
Revenue Q2Q9.00%
EPS Q2Q-46.20%
Number of Analysts6
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
0.00%
EPS (1 Month)
0.00%
EPS (3 Months)
-37.66%
Next Earnings Summary
VNDA is expected to report earnings on 5/5/2026. The consensus EPS estimate for the next earnings is -0.73 USD and the consensus revenue estimate is 54.55M USD.
The next earnings revenue estimate has been revised downward by 0% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 254.4M -5.32% | 192.64M -24.28% | 198.772M 3.18% | 222.64M 12.01% | 272.72M 22.49% | 357.31M 31.02% | 427.72M 19.71% | 215.22M -49.68% | 197.88M -8.06% | |
| EBITDA YoY % growth | 9M -86.13% | -10.942M -221.58% | -32.528M -197.28% | -38.046M -16.96% | 12.138M 131.90% | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | 6.3M -89.84% | -13.952M -321.46% | -40.66M -191.43% | -144.628M -255.70% | -144.876M -0.17% | -64.293M 55.62% | -22.984M 64.25% | -43.86M -90.83% | -64.26M -46.51% | |
| Operating Margin | 2.48% | -7.24% | -20.46% | -64.96% | -53.12% | -17.99% | -5.37% | -20.38% | -32.47% | |
| EPS YoY % growth | 0.12 -79.31% | 0.05 -58.33% | -0.32 -740.00% | -2.73 -462.50% | -1.48 17.97% | -0.77 48.19% | N/A | N/A | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.73 -46.20% | -0.60 -30.09% | -0.32 15.00% | -0.33 28.31% |
| Revenue Q2Q % growth | 54.545M 9.00% | 61.71M 17.34% | 73.134M 30.00% | 75.208M 31.45% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -48.521M -18.26% | -38.94M -1.14% | -31.518M -0.75% | -33.609M -6.50% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
N/A
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
24.31%
Revenue Next 5 Year
-2.33%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
VANDA PHARMACEUTICALS INC / VNDA Forecast FAQ
What is the average price target for VANDA PHARMACEUTICALS INC (VNDA) stock?
10 analysts have analysed VNDA and the average price target is 14.41 USD. This implies a price increase of 86.63% is expected in the next year compared to the current price of 7.72.
When does VANDA PHARMACEUTICALS INC (VNDA) report earnings?
VANDA PHARMACEUTICALS INC (VNDA) will report earnings on 2026-05-05.
What are the consensus estimates for VNDA stock next earnings?
The consensus EPS estimate for the next earnings of VANDA PHARMACEUTICALS INC (VNDA) is -0.73 USD and the consensus revenue estimate is 54.55M USD.
What is the consensus rating for VNDA stock?
The consensus rating for VANDA PHARMACEUTICALS INC (VNDA) is 80 / 100 . This indicates that analysts generally have a positive outlook on the stock.